Last reviewed · How we verify
Locoid (HYDROCORTISONE BUTYRATE)
Locoid works by binding to the glucocorticoid receptor, triggering a response that reduces inflammation and immune responses.
Locoid (HYDROCORTISONE BUTYRATE) is a corticosteroid medication developed by PRECISION DERMAT and currently owned by Bausch. It targets the glucocorticoid receptor to exert its effects. Approved in 1982, it is used to treat various skin conditions. As an off-patent medication, it is available from multiple generic manufacturers. Key considerations include its potency and potential side effects.
At a glance
| Generic name | HYDROCORTISONE BUTYRATE |
|---|---|
| Sponsor | Bausch Health |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1982 |
Mechanism of action
Topical corticosteroids share anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical corticosteroids is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Approved indications
Common side effects
- rash
- pimples
- formation of pus
- discolored skin
- thin skin
- burning or prickly feeling
Key clinical trials
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- Improvement of Psoriasis Patients' Adherence to Topical Drugs (NA)
- A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD (PHASE4)
- Treatment of Tracheostomy Granulomas (PHASE4)
- Local Steroid Treatment for Idiopathic Granulomatous Mastitis (LSTIGM) (PHASE4)
- Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents (NA)
- Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy (PHASE3)
- Evaluation of the Vasoconstriction Properties of MC2-01 Cream (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |